Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer

Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting is associated with improved EFS. Whether NCT pr...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Palmieri, Carlo, Macpherson, Iain RJ, Yan, Kelvin, Ades, Felipe, Riddle, Pippa, Ahmed, Riz, Owadally, Waheeda, Stanley, Barbara, Shah, Deep, Gojis, Ondrej, Januszewski, Adam, Lewanski, Conrad, Asher, Rebecca, Lythgoe, Daniel, de Azambuja, Evandro, Beresford, Mark, Howell, Sacha J.
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2015
נושאים:
Clinical Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4914352/
https://ncbi.nlm.nih.gov/pubmed/26334099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.4801
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים